Platelet Inhibition, Endothelial Function, and Clinical Outcome in Patients Presenting With ST-Segment-Elevation Myocardial Infarction Randomized to Ticagrelor Versus Prasugrel Maintenance Therapy: Long-Term Follow-Up of the REDUCE-MVI Trial.

导出 OA

翻译打印收藏纠错

作者： Nina W,van der Hoeven ^[1] ; Gladys N,Janssens ^[1] ; Henk,Everaars ^[1] ; Alexander,Nap ^[1] ; Jorrit S,Lemkes ^[1] ; Guus A,de Waard ^[1] ; Peter M,van de Ven ^[2] ; Albert C,van Rossum ^[1] ; Javier,Escaned ^[3] ; Hernan,Mejia-Renteria ^[3] ; Tim J F,Ten Cate ^[4] ; Jan J,Piek ^[5] ; Clemens,von Birgelen ^[6] ; Marco,Valgimigli ^[7] ; Roberto,Diletti ^[8] ; Niels P,Riksen ^[1] ; Nicolas M,Van Mieghem ^[9] ; Robin,Nijveldt ^[8] ; Maarten A H,van Leeuwen ^[1] ; Niels,van Royen ^[4]

作者单位： Department of Cardiology Amsterdam UMC Vrije Universiteit Amsterdam Amsterdam Cardiovascular Sciences Amsterdam the Netherlands. ^[1] Department of Epidemiology and Biostatistics Amsterdam UMC Vrije Universiteit Amsterdam Amsterdam Cardiovascular Sciences Amsterdam the Netherlands. ^[2] Hospital Clínico San Carlos IDISSC and Universidad Complutense de Madrid Madrid Spain. ^[3] Department of Cardiology Radboud University Medical Center Nijmegen the Netherlands. ^[4] Department of Cardiology Amsterdam UMC Academic Medical Center Amsterdam Cardiovascular Sciences Amsterdam the Netherlands. ^[5] Department of Cardiology Medisch Spectrum Twente Enschede the Netherlands. ^[6] Department of Cardiology Bern University Hospital Bern Switzerland. ^[7] Department of Cardiology Erasmus MC Rotterdam the Netherlands. ^[8] Department of Internal Medicine Radboud University Medical Center Nijmegen the Netherlands. ^[9] Department of Cardiology Isala Heart Centre Zwolle the Netherlands. ^[10]

关键词 ST‐segment‐elevation myocardial infarction endothelial function microvascular injury platelet inhibition prasugrel ticagrelor